Your browser doesn't support javascript.
loading
Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
Astolfi, Andrea; Kudolo, Mark; Brea, Jose; Manni, Giorgia; Manfroni, Giuseppe; Palazzotti, Deborah; Sabatini, Stefano; Cecchetti, Federica; Felicetti, Tommaso; Cannalire, Rolando; Massari, Serena; Tabarrini, Oriana; Loza, Maria Isabel; Fallarino, Francesca; Cecchetti, Violetta; Laufer, Stefan A; Barreca, Maria Letizia.
Affiliation
  • Astolfi A; Department of Pharmaceutical Sciences, "Department of Excellence 2018-2022", University of Perugia, Via del Liceo 1, 06123, Perugia, Italy.
  • Kudolo M; Department of Pharmaceutical & Medicinal Chemistry, Institute of Pharmacy, Eberhard-Karls University Tuebingen, Auf der Morgenstelle 8, 72076, Tuebingen, Germany.
  • Brea J; CIMUS Research Center, University of Santiago de Compostela, Avda de Barcelona s/n, Planta 3, Despacho1, 15782, Santiago de Compostela, Spain.
  • Manni G; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli, 06100, Perugia, Italy.
  • Manfroni G; Department of Pharmaceutical Sciences, "Department of Excellence 2018-2022", University of Perugia, Via del Liceo 1, 06123, Perugia, Italy.
  • Palazzotti D; Department of Pharmaceutical Sciences, "Department of Excellence 2018-2022", University of Perugia, Via del Liceo 1, 06123, Perugia, Italy.
  • Sabatini S; Department of Pharmaceutical Sciences, "Department of Excellence 2018-2022", University of Perugia, Via del Liceo 1, 06123, Perugia, Italy.
  • Cecchetti F; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli, 06100, Perugia, Italy.
  • Felicetti T; Department of Pharmaceutical Sciences, "Department of Excellence 2018-2022", University of Perugia, Via del Liceo 1, 06123, Perugia, Italy.
  • Cannalire R; Department of Pharmaceutical Sciences, "Department of Excellence 2018-2022", University of Perugia, Via del Liceo 1, 06123, Perugia, Italy.
  • Massari S; Department of Pharmaceutical Sciences, "Department of Excellence 2018-2022", University of Perugia, Via del Liceo 1, 06123, Perugia, Italy.
  • Tabarrini O; Department of Pharmaceutical Sciences, "Department of Excellence 2018-2022", University of Perugia, Via del Liceo 1, 06123, Perugia, Italy.
  • Loza MI; CIMUS Research Center, University of Santiago de Compostela, Avda de Barcelona s/n, Planta 3, Despacho1, 15782, Santiago de Compostela, Spain.
  • Fallarino F; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli, 06100, Perugia, Italy.
  • Cecchetti V; Department of Pharmaceutical Sciences, "Department of Excellence 2018-2022", University of Perugia, Via del Liceo 1, 06123, Perugia, Italy.
  • Laufer SA; Department of Pharmaceutical & Medicinal Chemistry, Institute of Pharmacy, Eberhard-Karls University Tuebingen, Auf der Morgenstelle 8, 72076, Tuebingen, Germany.
  • Barreca ML; Department of Pharmaceutical Sciences, "Department of Excellence 2018-2022", University of Perugia, Via del Liceo 1, 06123, Perugia, Italy. Electronic address: maria.barreca@unipg.it.
Eur J Med Chem ; 182: 111624, 2019 Nov 15.
Article in En | MEDLINE | ID: mdl-31445234
ABSTRACT
This work describes the rational discovery of novel chemotypes of p38α MAPK inhibitors using a funnel approach consisting of several computer-aided drug discovery methods and biological experiments. Among the identified hits, four compounds belonging to different chemical families showed IC50 values lower than 10 µM. In particular, the 1,4-benzodioxane derivative 5 turned out to be a potent and efficient p38α MAPK inhibitor having IC50 = 0.07 µM, and LEexp and LipE values of 0.38 and 4.8, respectively; noteworthy, the compound had also a promising kinase selectivity profile and the capability to suppress p38α MAPK effects in human immune cells. Overall, the collected findings highlight that the applied strategy has been successful in generating chemical novelty in the inhibitor kinase field, providing suitable chemical candidates for further inhibitor optimization.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Mitogen-Activated Protein Kinase 14 / Protein Kinase Inhibitors / Drug Discovery Type of study: Diagnostic_studies / Prognostic_studies / Screening_studies Language: En Journal: Eur J Med Chem Year: 2019 Type: Article Affiliation country: Italy

Full text: 1 Database: MEDLINE Main subject: Mitogen-Activated Protein Kinase 14 / Protein Kinase Inhibitors / Drug Discovery Type of study: Diagnostic_studies / Prognostic_studies / Screening_studies Language: En Journal: Eur J Med Chem Year: 2019 Type: Article Affiliation country: Italy